Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00386685
Status:
COMPLETED
Last Update Posted:
2011-04-12
First Post:
2006-10-10
Brief Title:
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Open Label Uncontrolled Study of XRP9881 in Combination With Trastuzumab Herceptin in Patients With HER2 Positive Metastatic Breast Cancer MBC
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab
The secondary objectives are safety and pharmacokinetic interaction
The secondary objectives are safety and pharmacokinetic interaction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| XRP9881 | None | None | None |